Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	20
Overall Study	STARTED	Ecallantide 10 mg	20
Overall Study	STARTED	Ecallantide 30 mg	19
Overall Study	STARTED	Ecallantide 60mg	20
Overall Study	COMPLETED	Placebo	18
Overall Study	COMPLETED	Ecallantide 10 mg	20
Overall Study	COMPLETED	Ecallantide 30 mg	19
Overall Study	COMPLETED	Ecallantide 60mg	19
Overall Study	NOT COMPLETED	Placebo	2
Overall Study	NOT COMPLETED	Ecallantide 10 mg	0
Overall Study	NOT COMPLETED	Ecallantide 30 mg	0
Overall Study	NOT COMPLETED	Ecallantide 60mg	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01343823/flow